Metoclopramide G.L. Pharma

Metoclopramide, the active ingredient in Metoclopramide G.L. Pharma, is a dopamine antagonist (antiemetic, gastro‑prokinetic) presented as an injectable solution for intramuscular and intravenous use. It is employed to prevent and treat nausea, vomiting, gastroparesis and related gastrointestinal motility disorders in adult patients.

GNH USA supplies Metoclopramide G.L. Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on dopamine pathways and gastrointestinal motility to manage several conditions. - Nausea and vomiting: reduces episodes in postoperative, chemotherapy‑induced or other causes. - Gastroparesis: improves gastric emptying and symptom relief. - Postoperative gastric stasis: facilitates return of normal gastric function after surgery. - Gastro‑oesophageal reflux disease (adjunct): assists in reducing reflux symptoms by enhancing gastric clearance.

Metoclopramide may cause a range of adverse reactions.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or akathisia - Diarrhea - Dry mouth - Headache

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, parkinsonism) - Tardive dyskinesia - Neuroleptic malignant syndrome - Severe allergic reactions (anaphylaxis, skin rash) - Depression or suicidal thoughts - Seizures

Use Metoclopramide with clinical caution and monitor patients closely. - Renal or hepatic impairment: adjust dose or monitor levels. - Parkinsonian disorders: avoid or use only if benefits outweigh risks. - Known hypersensitivity: discontinue immediately. - Depression or suicidal ideation: observe for mood changes. - Use the lowest effective dose for the shortest duration needed. - Store at room temperature: keep in the original container, protect from moisture and light.

Metoclopramide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol) – additive dopamine blockade. - Monoamine oxidase inhibitors – increased risk of hypertensive crisis. - Central nervous system depressants (opioids, benzodiazepines) – enhanced sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine) – may raise metoclopramide levels. - Anticholinergic agents – may reduce pro‑kinetic efficacy.